Market capitalization | €1.88b |
Enterprise Value | €2.80b |
P/E (TTM) P/E ratio | 22.63 |
EV/FCF (TTM) EV/FCF | 27.82 |
EV/Sales (TTM) EV/Sales | 2.47 |
P/S ratio (TTM) P/S ratio | 1.66 |
P/B ratio (TTM) P/B ratio | 3.41 |
Dividend yield | 2.52% |
Last dividend (FY23) | €0.88 |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
3 Analysts have issued a Dermapharm forecast:
3 Analysts have issued a Dermapharm forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,132 1,132 |
0%
0%
|
|
Gross Profit | 354 354 |
14%
14%
|
|
EBITDA | 295 295 |
26%
26%
|
EBIT (Operating Income) EBIT | 196 196 |
35%
35%
|
Net Profit | 83 83 |
32%
32%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dermapharm Holding SE engages in the development, manufacture. and market of patent-free pharmaceutical products. The company also involves in in-house development, in-house production, and distribution of pharmaceuticals and other healthcare products. It offers its products through the following brands: Dekristol 20,000 I.E., bite away, Herpotherm, sikapur, Ampho-Moronal, Solacutan, Ciclocutan, Minoxicutan, Prednisolut, Dienovel, Lactofem, Finapil, Panthenol-Augensalbe JENAPHARM, and Suxilep. The company was founded in 1991 and is headquartered in Grunwald, Germany.
Head office | Germany |
CEO | Hans-Georg Feldmeier |
Founded | 1991 |
Website | www.dermapharm.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.